Neurocrine stock rockets to a record on sales beat—but can it last? By: MarketWatch November 03, 2017 at 06:59 AM EDT Neurocrine charged many patients twice the price of the drug in the latest quarter—but it is coming to an end. Read More >> Related Stocks: Neurocrine Bioscienc Standard & Poors 500